mutLBSgeneDB |
Gene summary for CDC34 |
![]() |
Basic gene Info. | Gene symbol | CDC34 |
Gene name | cell division cycle 34 | |
Synonyms | E2-CDC34|UBC3|UBCH3|UBE2R1 | |
Cytomap | UCSC genome browser: 19p13.3 | |
Type of gene | protein-coding | |
RefGenes | NM_004359.1, | |
Description | cell division cycle 34 homologubiquitin carrier proteinubiquitin-conjugating enzyme E2 R1ubiquitin-conjugating enzyme E2-32 KDA complementingubiquitin-conjugating enzyme E2-CDC34ubiquitin-protein ligase R1 | |
Modification date | 20141207 | |
dbXrefs | MIM : 116948 | |
HGNC : HGNC | ||
Ensembl : ENSG00000099804 | ||
HPRD : 00306 | ||
Vega : OTTHUMG00000180558 | ||
Protein | UniProt: P49427 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_CDC34 | |
BioGPS: 997 | ||
Pathway | NCI Pathway Interaction Database: CDC34 | |
KEGG: CDC34 | ||
REACTOME: CDC34 | ||
Pathway Commons: CDC34 | ||
Context | iHOP: CDC34 | |
ligand binding site mutation search in PubMed: CDC34 | ||
UCL Cancer Institute: CDC34 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID | GO:0000209 | protein polyubiquitination | 20347421 | GO:0016567 | protein ubiquitination | 10373550 | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 10373550 | GO:0043951 | negative regulation of cAMP-mediated signaling | 10373550 | GO:0070936 | protein K48-linked ubiquitination | 20061386 |
Top |
Ligand binding site mutations for CDC34 |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | F58 | A60V | COAD | 1 | E26 | E26K | HNSC | 1 | Y148 | V146L | LUAD | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for CDC34 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | F58 | A60V | 0.22237353 | E26 | E26K | -0.77065307 | Y148 | V146L | -0.18162199 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for CDC34 |
![]() |
![]() |
Top |
Top |
Phenotype information for CDC34 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for CDC34 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | C | E26 F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | D | E26 F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | A | F58 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | B | F58 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | C | F58 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 3rz3 | B | F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | A | F58 Y148 | U94 | 4,5-DIDEOXY-5-(3',5'-DICHLOROBIPHENYL-4-YL)-4-[(METHOXYACETYL)AMINO]-L-ARABINONIC ACID | 4mdk | D | F58 Y148 |
Top |
Conservation information for LBS of CDC34 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |